Today: 11 June 2026
Gold price today back above $5,000 as dollar slips; U.S. jobs and CPI are next
9 February 2026
1 min read

Gold price today back above $5,000 as dollar slips; U.S. jobs and CPI are next

New York, February 9, 2026, 13:34 EST — Regular session

  • Spot gold jumped roughly 2%, climbing past $5,000 an ounce as the U.S. dollar softened.
  • Traders waited for U.S. jobs numbers and inflation data, both pushed back to later this week.
  • China’s central bank picked up more gold in January, stretching its buying streak further.

Gold climbed past $5,000 an ounce again Monday, with a softer U.S. dollar and traders looking ahead to a packed week of U.S. economic data—numbers that might shake up rate expectations.

The swing is significant—gold doesn’t yield interest, so it usually outperforms when rate expectations drop and the dollar loses steam. This week’s figures arrive in the wake of choppy trading, with bullion turning into a fast-moving gauge for policy risk.

Rates traders are increasingly betting on looser policy in 2026, and gold seems to be catching the signal. Softer labor and inflation data might keep buyers coming for bullion. But if the data flips the other way, brace for another sharp pullback.

Spot gold jumped 2.1% to $5,063.88 an ounce as of 11:12 a.m. ET. April U.S. gold futures moved up 2.2% to $5,087.10. “The big mover was the U.S. dollar,” said TD Securities strategist Bart Melek, noting that “the debasement trade continues” with geopolitical risks propping up demand. Investors are zeroed in on the delayed U.S. nonfarm payrolls report this week, plus jobless claims and consumer prices, with markets factoring in at least two 25-basis-point rate cuts—each 0.25 percentage point—in 2026. Reuters

The April gold contract (GCJ6) climbed 2.43% to $5,100.7 an ounce in recent trading on CME Group’s Globex, according to CME data. Volume was running close to 94,711 just before 11 a.m. CT.

China hasn’t stepped back. The People’s Bank of China kept up its gold purchases for a fifteenth straight month in January, bumping reserves to 74.19 million fine troy ounces by month’s end, according to Reuters. The value of those holdings moved higher as well. It’s been a volatile year for gold — prices hit an all-time high close to $5,600 in January before tumbling to $4,403.24 on Feb. 2, after Kevin Warsh was tapped to lead the Fed.

Silver, along with platinum group metals, climbed too—buoyed not just by the weaker dollar but by a wider rush into hard assets.

The rally’s on shaky ground when it comes to the data. A hot payrolls or inflation print, and suddenly the dollar and bond yields could snap higher—making interest-bearing assets look more attractive, and sending gold back down.

Friday brings the next major test for traders: the January U.S. consumer price index, out at 8:30 a.m. ET on Feb. 13, per the Labor Department’s calendar.

Stock Market Today

  • Banco BPM Stock Valuation Reviewed as Shares Rise Amid Earnings Momentum
    June 11, 2026, 11:13 AM EDT. Banco BPM (BIT:BAMI) has posted robust share price gains of 8.85% in the past month and 51.01% over the last year, driven by strong earnings with revenue of €5.42 billion and net income of €2.05 billion. Despite recent appreciation, analysts see the stock as slightly overvalued at a consensus fair value of €13.71, below the current price of €14.03. Banco BPM trades at a price-to-earnings (P/E) ratio of 10.3 times, below European bank peers at 11.3 times, suggesting some valuation cushion. However, risks such as increased fintech competition and challenges in cost efficiencies remain. Investor focus is on whether current momentum fully reflects growth expectations or leaves room for further upside.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open
Previous Story

JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view
Next Story

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view

Go toTop